RT Journal Article
SR Electronic
T1 Investigation of the causative pathogen in the 2023 conjunctivitis outbreak of Nepal using unbiased metagenomic next generation sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.16.24305920
DO 10.1101/2024.04.16.24305920
A1 Shrestha, Eliya
A1 Katuwal, Nishan
A1 Kharel Sitaula, Ranju
A1 Gurung, Harimaya
A1 Shrestha, Aastha
A1 Karki, Pratap
A1 Shrestha, Rajeev
YR 2024
UL http://medrxiv.org/content/early/2024/04/19/2024.04.16.24305920.abstract
AB In mid-2023, Nepal experienced a significant outbreak of conjunctivitis, affecting over 60% of outpatients in eye hospitals and prompting school closures. The outbreak, peaking in August, predominantly impacted children and individuals with compromised immunity. Clinical manifestations included sudden-onset redness, foreign body sensation, watery discharge, and occasional lid swelling. A majority of cases exhibited acute hemorrhagic conjunctivitis, with management involving ocular lubricants, personal hygiene, and topical antibiotics. This study details the genomic epidemiology and clinical characteristics of conjunctivitis cases during the outbreak. To understand the causative agents, conjunctival swabs from patients were evaluated using unbiased metagenomic next-generation sequencing (mNGS) in Illumina iSeq100 at Dhulikhel Hospital Kathmandu University Hospital. This case series revealed the presence of Enterovirus C (coxsackievirus strain A24) as the major pathogen responsible for the outbreak. This case series contributes valuable insights into the genomic diversity of conjunctivitis-associated viruses, highlighting the potential of mNGS in enhancing diagnostic capabilities and guiding public health responses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was ethically cleared from IRC-KUSMS. This study directly did not contact the human subjects and investigated stored conjunctival samples and secondary clinical and demographic metadata.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data generated or analyzed during this study are included in this article.